

hibitory activities of these McAb: OX4 and 10.2-16 McAb inhibited T-cell proliferation by 50-60%, whereas 13/4 McAb induced approximately 40% inhibition of this response. Normal mouse IgG did not cause inhibition of the response to Ig $\kappa$ -1b AG and PPD.

The results are thus evidence of restriction of Ig $\kappa$ -1b-specific proliferation of August rat T-cells in vitro with respect mainly to products of the RT-1B<sup>C</sup> subregion of rat MHC. It can be tentatively suggested that allotype-specific T lymphocytes recognize Ig $\kappa$ -1b AG determinants in combination with determinants of RT-1B molecules, revealed by OX4 and 10.2-16 McAb. However, Ir-genetic control and MHC restriction of the T-cells response are linked by definition with polymorphic determinants of histocompatibility antigens. The most likely explanation of the observed inhibition of the T-cell response to Ig $\kappa$ -1b AG is therefore steric screening of polymorphic determinants of RT-1B molecules, by these McAb, restricting the T-cell response to this antigen. A less likely explanation is modulation of the density of the surface RT-1B molecules of AG presenting cells as a result of their interactions with McAb. The results of several investigations have yielded evidence of weak modulation of surface MHC-molecules under the influence of McAb [7]. These two interpretations of the results do not contradict the general conclusion of restriction of T-cell recognition of allotypic Ig $\kappa$ -1b determinants of serum Ig with respect to products of the RT-1B subregion of rat MHC.

#### LITERATURE CITED

1. A. Yu. Rudenskii and V. L. Yurin, Byull. Éksp. Biol. Med., No. 6, 719 (1986).
2. V. L. Yurin, A. Uspenskii, and I. M. Meinert, Byull. Éksp. Biol. Med., No. 1, 44 (1977).
3. V. L. Yurin and L. D. Dunaevskaya, Immunologiya, No. 4, 40 (1980).
4. J. Frelinger, L. Hood, and P. Wettstein, Transplant. Proc., 13, 1360 (1981).
5. P. Jones, V. Oi, J. Goding, and L. A. Herzenberg, Curr. Top. Microbiol. Immunol., 81, 115 (1978).
6. U. K. Laemmli, Nature, 227, 680 (1970).
7. B. Pernis, Immunol. Today, 6, 45 (1985).

#### CYTOTOXIC PROPERTIES OF A CONJUGATE OF RICIN A CHAIN AND ANTIALLOTYPIC MONOCLONAL ANTIBODIES

V. A. Rakhmanova, A. G. Tonevitskii,  
V. V. Cherepakhin, and R. A. Bobreneva

UDC 615.275.2:547.962.3].015.46

KEY WORDS: immunotoxin; ricin A chain; antiallotypic antibodies

Immunotoxins (IT), which are conjugates of plant or bacterial toxins with antibodies, are a new class of highly specific pharmacologic agents which may be used for the oriented elimination of a particular population of target cells. Many IT so far obtained have a selective cytotoxic action on tumor cells in culture [8, 10, 13]. The use of IT in an in vitro system, i.e., direct introduction of the conjugate into the body, is particularly interesting. However, the results of such investigations have proved rather contradictory [6, 9].

The aim of this investigation was to obtain a conjugate of ricin A chain (R<sub>A</sub>) and of monoclonal antibodies to an allelic variant of the L-chain of rat Ig (Ig $\kappa$ -1a) and to study its ability to inhibit growth of cells carrying Ig with the 1a allotype in in vitro systems and on direct administration to rats.

---

Laboratory of Immunology, All-Union Research Institute of Genetics and Selection of Industrial Microorganisms, Ministry of the Medical and Biological Industry of the USSR. Laboratory of Immunology, All-Union Research Institute of Experimental Cardiology, All-Union Cardiology Scientific Center, Academy of Medical Sciences of the USSR, Moscow. (Presented by Academician of the Academy of Medical Sciences of the USSR V. N. Smirnov.) Translated from Byulleten' Éksperimental'noi Biologii i Meditsiny, Vol. 105, No. 5, pp. 568-570, May, 1988. Original article submitted April 10, 1987.




Fig. 1




Fig. 2

Fig. 1. Densitogram of stained gel after polyacrylamide gel electrophoresis (acrylamide concentration gradient 7-22%) in a) IT containing 1  $R_A$  molecule to 1 antibody molecule; b) modified antibodies (150 kD); c) isolated  $R_A$  (32 kD).

Fig. 2. Cytotoxic action of IT and its component parts. a) Spleen cells treated with IT (anti-la- $R_A$ ), 65  $\mu$ g; b) treated with monoclonal anti-la-antibodies, 45  $\mu$ g; c) treated with  $R_A$ , 25  $\mu$ g; d) with 0.1 M phosphate buffer, pH 7.5 with 0.1 M NaCl. Cells washed off and incubated with rabbit polyclonal monospecific antibodies (1 - anti-la, 2 - anti-lb, 3 - anti-IgG, 4 - anti-IgM) obtained as described previously [2, 3], and also with normal rabbit IgG for 20 min, and subsequently with fluorescein isothiocyanates-labeled goat anti-rabbit Ig (Cappel, USA). Antibodies for incubation were used in a concentration of 100  $\mu$ g/ml in 50  $\mu$ l PBS with 1% bovine serum albumin. After each incubation the cells were washed off 3 times with PBS. All procedures were carried out at 4°C. The preparations were examined in the ICM 405 luminescence microscope (Opton, West Germany). The experiment was carried out in three parallel repetitions. Ordinate - number of fluorescent cells among 500 counted.

#### EXPERIMENTAL METHOD

Monoclonal antiallotypic (anti-la) antibodies of the IgG1, k isotype [7] were used.

The isolation of ricin and its isolated subunits and obtaining of a conjugate of antibodies and  $R_A$ , with the aid of N-succinimidyl-3-(2-pyridyldithio)-propionate and their analysis were described in detail previously [4].

Activity of the conjugate and antibodies in cell culture was determined by recording inhibition of growth of cells carrying the corresponding antigen. Splenocytes ( $6 \times 10^6$  cells/ml) of heterozygous  $F_1$  rats obtained by crossing MSU females (Igk-lb-allotype) with AGU males (Igk-la-allotype), in 1 ml of DMEM culture medium (Flow Laboratories, England) with 10% embryonic calf serum (Flow) were treated with preparations of IT, anti-la antibodies, and  $R_A$  for 1 h at 30°C, after which the cells were washed and transferred into flasks (25 cm<sup>2</sup>/50 ml, Nunc, Denmark). After 24 h the fraction of cells carrying IgM, IgG, and also Ig with L-chains of the lb or la allotype was determined by the immunofluorescence test (IFT).

To determine the inhibitory action of IT in vivo, monoclonal anti-la antibodies,  $R_A$ , and IT were injected into  $F_1$  hybrids 10 days after birth, after which their cytotoxic action was determined by analyzing the levels of Ig with la- and lb-allotypes. The preparations were injected intraperitoneally in a volume of 0.5 ml in PBS (0.15 M NaCl, 5 mM Na-phosphate buffer, pH 7.5). Antibodies,  $R_A$ , and IT were injected in single doses of 100, 50, and 60  $\mu$ g respectively. Suppressive action of the antibodies also was determined after their injection in two doses each of 50  $\mu$ g on the 10th and 12th days after birth of the rats.

For quantitative determination of allotypic variants of immunoglobulins in the serum of the heterozygous rats, the radioimmunoabsorption inhibition method was used [12]. Inhibition was carried out to antiallotypic rabbit antibodies fixed to cellulose [1].




Fig. 3. Concentrations of Ig with la- and lb-allotypes in serum of rats after injection of antibodies (columns from left to right: 100 µg, 50 µg + 50 µg; 50 µg RA, and 60 µg IT). Concentration of la-allotype (a) and of lb-allotype (b) determined in animals aged 30 (1) and 60 days (2). To each sample for incubation 50 µl of anti-lb-sorbent and 5 µl of anti-la-sorbent were added. The total volume of sorbent was made up to 250 µl by sorbent with fixed bovine serum albumin. Unlabeled proteins in 0.5 ml PBS with 5% bovine serum were added to the residue of the sorbent and incubated for 1 h at room temperature. To each sample were then added 0.5 ml of  $^{125}\text{I}$ -IgG MSU and  $^{125}\text{I}$ -IgG AUG in the same buffer, after which they were incubated for a further 1 h under the same conditions. Specific activity of the preparations labeled by the method in [5] was 500,000 cpm/µg. The sorbent was washed off and its radioactivity counted on a gamma-spectrometer (Minigamma 1275 or RackGamma 1270 for LKB, Sweden). The level of free sorption reached 11,000 cpm. Ordinate, Ig concentration (in mg/ml); arrow indicates Ig level in intact rats of the same age.

#### EXPERIMENTAL RESULTS

The qualitative composition of the IT thus obtained is illustrated on the densitogram (Fig. 1). The conjugate contained one RA molecule to one antibody molecule. The conjugation efficiency, i.e., the percentage of antibodies bound with toxin, was 52. Thus the IT preparation (60 µg) was a mixture of conjugate (27 µg), antibodies (25 µg), and RA (8 µg).

The cytotoxic properties of the IT and its components were determined by studying inhibition of growth of the number of antigen-carrying cells in the culture. Spleen cells of heterozygous rats were treated with IT, antibodies, and RA, after which the composition of this cell population was analyzed quantitatively by the IFT (Fig. 2). After treatment of the spleen cells with IT in a concentration of  $10^{-7}$  M the number of spleen cells carrying L-chains with the la-allotype was reduced by 21 times compared with the number of cells treated with buffer. RA and monoclonal antibodies (anti-la) in concentrations of  $6 \cdot 10^{-7}$  and  $2 \cdot 10^{-7}$  M, respectively reduced the number of cells with the Igk-la-allotype slightly (by 1.7 times).

The very weak action of IT on cells carrying L-chains with the other allotype (Igk-lb) was virtually identical with the action of isolated antibodies and RA.

The anti-la-RA conjugate thus exerts a selective cytotoxic action on target cells carrying L-chains with the la-allotype, but had no effect on cells carrying the other (lb) allotype.

The action of the IT obtained as described above also was tested in an in vivo system. The conjugate was injected into heterozygous (MSU × AUG) rats at the age of 10 days. It was shown that in young rats of this age the concentration of Ig with the la-allotype in the serum is not more than  $7 \cdot 10^{-3}$  mg/ml, whereas the concentration of Ig with the lb-allotype was 5 mg/ml. The concentration of Ig with lb- and la-allotypic determinants in the serum of the young rats (aged 30 and 60 days) receiving injections of the preparations were determined by the radioimmunoabsorption inhibition test. Each group studied consisted of seven rats. The results are given in Fig. 3.

In rats aged 30 days partial inhibition of synthesis of the Igk-la-allotypic variant was observed: 1) after a single injection of 100 µg of antibodies (anti-la); 2) after injection of 60 µg of the IT preparation. The same decrease in content of Ig with the la-allotype as under normal conditions was observed in the rats of these groups 50 days after injection.

In the case of two injections of antibodies (50  $\mu$ g on the 10th and again on the 12th day after birth) the serum concentration of allotypic variants of Ig in the rats was unchanged compared with normal. It will be clear from Fig. 3 that injection of  $1.5 \cdot 10^{-10}$  mole (27  $\mu$ g) of the conjugate reduced production of Ig with the Ia-allotype to the same degree as injection of  $6.7 \cdot 10^{-10}$  mole (100  $\mu$ g) of anti-Ia-antibodies, i.e., IT suppresses the Igk-Ia-allotype 4.5 times more effectively than the isolated antibodies composing it.

After injection of  $R_A$  into rats aged 30 days no changes took place in the concentration of Ig with Ib- and Ia-allotypes, but an appreciable decrease in the quantity of Ig nonspecific for Ib- and Ia-allotypes was observed in rats on the 50th day after injection of the preparation. The concentrations of Ig with the Ia-allotype was reduced from 2.9 mg/ml in the intact rats to 1 mg/ml in rats treated with  $R_A$ , and the concentration of the Igk-Ib-allotype fell from 7.8 to 3.6 mg/ml respectively.

The results show that antiallotypic antibodies and IT containing these antibodies, if injected intraperitoneally into young rats aged 10 days, reduced the serum concentration of Ig with the Ia-allotype. The concentration of Ig with the Ia-allotype 20 days after injection of the preparation fell from 0.46 mg/ml in intact rats to 0.26 mg/ml in rats after treatment with antibodies and to 0.24 mg/ml after treatment with IT. The concentration of the Igk-Ia-allotype fell to 1.7 mg/ml 50 days after injection of antibodies and IT. In intact rats at this same age the concentration of Ig with the Ia-allotype was 2.9 mg/ml. The results demonstrate the immunospecific activity of antiallotypic IT both in vitro and in vivo. Meanwhile these data indicate that IT are much less effective in vivo if their action is assessed at the serum (Ia) Ig level. This may be connected with the small quantities of the conjugate reaching the target B cells in different anatomical situations.

The experimental model described above is promising for the study of the oriented action of immunotoxins in vivo on renewing and dissimulating cell populations. The problem of increasing the effectiveness of the conjugates when administered in vivo is of topical importance [11, 14] and requires further study.

#### LITERATURE CITED

1. A. E. Gurvich, Modern Methods in Biochemistry [in Russian], Vol. 1, Moscow (1964), pp. 73-97.
2. M. N. Petrosyan, A. N. Mats, A. R. Ibragimov, et al., Dokl. Akad. Nauk SSSR, 267, No. 4, 1002 (1982).
3. O. V. Rokhlin, Mol. Biol., 10, No. 1, 206 (1976).
4. A. G. Tonevitskii, Mol. Biol., 19, No. 4, 1034 (1985).
5. W. F. Bale, R. W. Helcamp, M. I. Izzo, et al., Proc. Soc. Exp. Biol. (New York), 122, 407 (1966).
6. I. F. Bumol, Q. C. Wong, and R. A. Reisfeld, Proc. Natl. Acad. Sci. USA, 80, 529 (1983).
7. V. V. Cherepakhin, A. V. Chervonsky, A. V. Filatov, and O. V. Rokhlin, Immunol. Lett., 10, 217 (1985).
8. D. G. Gilliland, Z. Steplewski, R. J. Collier, et al., Proc. Natl. Acad. Sci. USA, 77, 4539 (1980).
9. T. K. Jansen and H. E. Blythman, Immunol. Rev., 62, 185 (1982).
10. M. Kronke, J. M. Depper, W. J. Leonard, et al., Blood, 65, 1416 (1985).
11. S. Ramakrishnan and L. L. Houston, Cancer Res., 44, 1398 (1984).
12. O. V. Rokhlin, T. I. Vengerova, and R. S. Nezlin, Immunochemistry, 8, 525 (1971).
13. A. G. Tonevitskii (A. G. Tonevitsky), E. B. Mechetner, E. N. Rozinova, et al., Int. J. Cancer, 37, 263 (1986).
14. F. M. Uckin, R. C. Stong, R. J. Youle, and D. A. Vallera, J. Immunol., 134, 3504 (1985).